论文部分内容阅读
目的探讨早期联合脾氨肽口服冻干粉预防治疗下呼吸道感染的疗效。方法 60例支气管肺炎患儿,随机分为实验组与对照组,各30例。对照组给予常规治疗,实验组在常规治疗的基础上给予脾氨肽口服冻干粉,观察并总结两组患儿住院日、住院期间感染再发生率及出院1周内感染复发几率的不同。结果实验组平均住院日、住院期间呼吸道感染再发生率、出院1周内呼吸道感染再发生率均少于对照组,差异有统计学意义(P<0.05)。患儿无一例发生不良反应。结论脾氨肽口服冻干粉使用安全可靠,方便有效,可以减少住院日以及再感染几率,值得临床推广应用。
Objective To investigate the efficacy of early combined oral administration of splenic amniotic peptide in the prevention and treatment of lower respiratory tract infection. Methods Sixty children with bronchopneumonia were randomly divided into experimental group and control group, with 30 cases in each. The control group was given conventional treatment. The experimental group was treated with splenic amniotic peptide oral freeze-dried powder on the basis of routine treatment. The incidence of hospitalization, inpatient re-infection and recurrence probability within 1 week after discharge were observed and summarized. Results The average length of hospital stay, the frequency of recurrent respiratory infections during hospitalization and the frequency of recurrent respiratory infections within 1 week of discharge in the experimental group were all less than those in the control group (P <0.05). No case of adverse reactions in children. Conclusion Spleen ammonia peptide oral freeze-dried powder is safe and reliable, convenient and effective, can reduce the hospitalization days and the risk of re-infection, worthy of clinical promotion and application.